Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivuxolimab - Pfizer

Drug Profile

Ivuxolimab - Pfizer

Alternative Names: anti-OX40R-11D4; B110; OX 40; PF-04518600; PF-8600

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Dana-Farber Cancer Institute; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; University of Southern California
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Phase I/II Acute myeloid leukaemia; Squamous cell cancer
  • Phase I Follicular lymphoma

Most Recent Events

  • 10 Dec 2022 Phase-Ib development for Follicular lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA (IV) (NCT03636503)
  • 10 Dec 2022 Phase-Ib development for Follicular lymphoma (Combination therapy, First-line therapy) is ongoing in USA (IV) (NCT03636503)
  • 10 Dec 2022 Efficacy and adverse events data from a phase Ib trial in Follicular lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top